A phase III clinical trial ascertained that patients with de novo O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma that received nivolumab plus radiotherapy did not benefit from nivolumab (CheckMate-498) when compared to standard chemoradiotherapy [144]. This evidence concerns the gene MGMT and glioblastoma.